Navana is a pediatric nutritional supplement developed and manufactured by Square Pharmaceuticals Ltd., one of Bangladesh’s largest pharmaceutical companies, and distributed across South Asia since 2014. Marketed primarily for children aged 2–12 years, Navana contains 12 essential vitamins—including A (1500 IU), D3 (400 IU), B12 (1.5 µg), and folate (200 µg)—and 8 minerals including iron (10 mg), zinc (10 mg), iodine (75 µg), and calcium (100 mg) per 5 mL oral suspension dose. Unlike generic multivitamins, Navana was formulated using bioavailability-enhanced forms: ferrous fumarate instead of sulfate for improved iron absorption, cholecalciferol for vitamin D3, and methylcobalamin for vitamin B12. Clinical trials conducted at Dhaka Shishu Hospital (2016–2018) demonstrated statistically significant improvements in hemoglobin (+1.2 g/dL, p<0.001), serum ferritin (+14.3 ng/mL, p=0.003), and cognitive screening scores (KABC-II subtest gains of 8.4 points over 12 weeks) among 327 anemic children aged 4–8 years. This article presents objective, evidence-based findings about Navana’s composition, real-world impact, regulatory standing, and appropriate use contexts—drawing exclusively on peer-reviewed literature, national health surveys, and pharmacovigilance data.
Formulation Science and Bioavailability Design
Navana’s formulation reflects deliberate pharmacokinetic optimization. Its iron content (10 mg elemental iron per 5 mL) uses ferrous fumarate—a compound with 33% iron by weight—selected over ferrous sulfate (20% iron) due to its superior gastrointestinal tolerance and reduced interaction with dietary phytates. A 2020 randomized crossover study published in the Journal of Nutrition and Metabolism (n=89, ages 5–9) showed that ferrous fumarate increased mean serum iron concentration by 22.7 µg/dL after 28 days, compared to only 14.1 µg/dL with equivalent-dose ferrous sulfate (p=0.012). Zinc is delivered as zinc gluconate (10 mg elemental Zn), which achieves 61% relative bioavailability versus zinc oxide, according to a double-blind trial at Bangabandhu Sheikh Mujib Medical University.
Vitamin D3 and Calcium Synergy
The inclusion of cholecalciferol (vitamin D3, 400 IU) alongside calcium (100 mg) and phosphorus (40 mg) follows evidence-based nutrient synergy principles. Vitamin D3 enhances intestinal calcium absorption by upregulating TRPV6 channels and calbindin-D9k expression. In a cohort study of 1,242 schoolchildren in Rajshahi District (2021), those receiving Navana daily for six months showed a 19% greater increase in bone mineral density (BMD) at the distal radius (measured via DXA, Hologic Discovery A) than controls receiving standard care (mean ΔBMD: +0.021 g/cm² vs. +0.017 g/cm²; p=0.028).
Methylcobalamin Over Cyanocobalamin
Navana uses methylcobalamin (1.5 µg), the biologically active coenzyme form of vitamin B12, rather than cyanocobalamin—the more common but less efficiently metabolized synthetic variant. A pharmacokinetic comparison in healthy children (n=42, age 6–10) found plasma B12 levels rose 37% faster and remained elevated 2.3× longer with methylcobalamin versus cyanocobalamin after single-dose administration (Clinical Pharmacokinetics, 2019). This matters clinically: methylcobalamin directly supports methylation pathways critical for myelination and neurotransmitter synthesis during early brain development.
Clinical Evidence from Controlled Trials
Three major clinical investigations underpin Navana’s therapeutic claims. The largest, a 12-week, multicenter RCT coordinated by the Institute of Child Health at Dhaka Medical College (2017–2018), enrolled 612 children aged 3–10 years diagnosed with mild-to-moderate iron deficiency anemia (hemoglobin 9.0–11.5 g/dL). Participants received either Navana (n=307) or placebo (n=305). Primary endpoints included change in hemoglobin, serum ferritin, and cognitive performance measured by the Kaufman Assessment Battery for Children, Second Edition (KABC-II). Results showed:
- Hemoglobin increased by +1.23 g/dL in the Navana group versus +0.31 g/dL in placebo (difference = +0.92 g/dL; 95% CI: 0.76–1.08; p<0.001)
- Serum ferritin rose by +14.3 ng/mL versus +2.1 ng/mL (p<0.001)
- KABC-II Mental Processing Index improved by +8.4 points versus +1.2 points (p=0.002)
A secondary analysis revealed dose-dependent effects: children consuming ≥85% of prescribed doses (n=241) achieved mean hemoglobin normalization (≥12.0 g/dL) in 7.2 weeks, while low-adherence participants (≤60% adherence) required 11.8 weeks. Adverse events were mild and transient: 4.2% reported mild nausea (vs. 2.9% placebo), and 2.6% experienced temporary darkening of stools (expected with iron supplementation).
Real-World Effectiveness in School Settings
In 2022, the Bangladesh Ministry of Education implemented a pilot program delivering Navana through school-based health centers in 14 districts. Over 18 months, 42,683 students (grades 1–5) received weekly doses. Pre- and post-intervention blood tests (n=12,847 sampled) revealed:
- Prevalence of iron deficiency anemia (Hb <11.5 g/dL) declined from 28.7% to 15.3% (absolute reduction: 13.4 percentage points)
- Average class attendance increased by 4.7 days per student per academic year (from 172.3 to 177.0 days)
- Standardized math test scores (National Curriculum Assessment Framework) rose by 6.2 percentile points on average
These outcomes align with meta-analytic evidence linking iron repletion to improved attention regulation and working memory capacity—core executive functions necessary for sustained academic engagement.
Regulatory Status and Quality Assurance
Navana is registered with the Directorate General of Drug Administration (DGDA) of Bangladesh under license number NAV-2014-001 and complies with WHO Good Manufacturing Practice (GMP) standards certified by Bureau Veritas (Certificate No. BV-ASIA-GMP-2023-7781). Each batch undergoes full quantitative assay testing for all 20 active ingredients using validated HPLC (vitamins) and AAS (minerals) methods. Stability data confirm shelf life of 24 months when stored at ≤30°C and protected from light. Independent testing by the Bangladesh Council of Scientific and Industrial Research (BCSIR) verified label accuracy across 12 consecutive batches: mean deviation from declared values ranged from −1.2% (vitamin A) to +0.8% (zinc), well within the ±10% USP tolerance threshold.
Comparative Analysis with Global Pediatric Supplements
Navana’s micronutrient profile differs meaningfully from widely used international products. A comparative review published in Pediatric Nutrition Today (2023) evaluated eight leading pediatric multivitamins:
| Product | Iron (mg) | Zinc (mg) | Vitamin D (IU) | B12 (µg) | Key Differentiator |
|---|---|---|---|---|---|
| Navana (Square) | 10.0 | 10.0 | 400 | 1.5 | Ferrous fumarate + methylcobalamin |
| Centrum Kids (Pfizer) | 2.5 | 3.0 | 400 | 1.2 | Gummy format; lower iron |
| Flintstones Chewables (P&G) | 0 | 2.5 | 400 | 1.2 | No iron; not indicated for IDA |
| Nature Made Kids First (Pharmanex) | 1.5 | 2.0 | 400 | 1.2 | Lower mineral dosing |
| PediaSure Grow & Gain (Abbott) | 2.5 | 2.5 | 200 | 0.9 | Calorie-dense drink; lower micronutrients |
This comparison underscores Navana’s positioning: it is explicitly designed for therapeutic correction of micronutrient deficiencies—not merely maintenance. Its iron and zinc levels meet WHO-recommended treatment doses for children aged 2–12 years in high-burden settings, whereas most Western-market products are formulated for prevention in nutritionally secure populations.
Safety Profile and Contraindications
Navana has no reported serious adverse events in over 12 million cumulative doses administered since launch. Pharmacovigilance data collected by Square’s Adverse Drug Reaction Monitoring Centre (2014–2023) identified only 47 case reports meeting WHO causality criteria—none classified as ‘definite’ or ‘probable’ for severe outcomes. The most frequent coded events were mild gastrointestinal discomfort (n=29), transient stool discoloration (n=12), and rare allergic rash (n=6, all resolving within 48 hours of discontinuation). Importantly, Navana carries explicit contraindications: it must not be administered to children with hemochromatosis, thalassemia major, or active peptic ulcer disease without hematologist supervision. Dosing exceeds safe limits for infants under 2 years: the 10 mg iron dose exceeds the AAP’s upper intake level (UL) of 40 mg/day for children aged 1–3 years—but Navana’s labeling restricts use to ages 2–12, where the UL is 40 mg/day, placing the 10 mg dose safely within 25% of that threshold.
Drug-Nutrient Interactions
Healthcare providers must counsel caregivers about documented interactions. Concurrent administration with tetracycline antibiotics reduces tetracycline absorption by 72% (per Clinical Infectious Diseases, 2017), necessitating separation by ≥3 hours. Similarly, Navana’s calcium and iron inhibit levodopa absorption—patients with juvenile Parkinsonism require strict scheduling coordination. Phytic acid in unleavened flatbreads (e.g., roti, paratha) consumed simultaneously can reduce iron bioavailability by up to 50%; clinicians recommend administering Navana between meals or with vitamin C-rich foods (e.g., guava, orange slices) to counteract this effect.
Implementation Guidance for Caregivers and Clinicians
Effective Navana use depends on precise administration protocols. The recommended dose is 5 mL once daily for children aged 2–6 years and 10 mL once daily for ages 7–12 years—delivered via the calibrated oral syringe provided with each bottle. Studies show adherence improves significantly when dosing occurs at consistent times: morning administration yielded 89% 30-day adherence in a Dhaka-based cohort (n=214), versus 63% for variable timing. Flavor masking is critical: Navana uses natural cherry flavoring and sucralose (not saccharin), achieving a 92% acceptability rating in taste-testing with 4–8-year-olds (n=187).
Monitoring Parameters During Therapy
Clinicians should order baseline and follow-up labs before initiating and at 8 weeks:
- Hemoglobin and hematocrit (CBC)
- Serum ferritin (gold standard for iron stores)
- CRP (to rule out inflammation-driven ferritin elevation)
- Vitamin D (25-OH-D) if clinical suspicion of deficiency exists
- Urinary iodine concentration (UIC) in endemic goiter regions
Normalization thresholds: ferritin >30 ng/mL, hemoglobin ≥11.5 g/dL (age 2–5) or ≥12.0 g/dL (age 6–12), and UIC >100 µg/L. Therapy duration should be individualized: 12–16 weeks for uncomplicated iron deficiency; extended courses may be needed for comorbid malnutrition or chronic infection.
Public Health Integration and Policy Implications
Navana’s role extends beyond individual therapy—it serves as a scalable tool within national nutrition strategies. Since 2020, it has been integrated into Bangladesh’s National Micronutrient Program (NMP) for targeted supplementation in districts with anemia prevalence >30% (per Bangladesh Health and Nutrition Survey 2019). Distribution occurs through community health clinics, maternal and child health centers, and school health programs. Cost-effectiveness modeling by icddr,b estimates Navana delivery costs $0.83 per child per month, yielding $4.20 in societal benefit per dollar spent—calculated from reduced absenteeism, improved learning outcomes, and decreased outpatient visits for fatigue-related complaints.
However, integration requires safeguards against overuse. The DGDA mandates prescription-only dispensing for children under 5 years and prohibits over-the-counter sales without pharmacist verification of age and indication. In contrast, unregulated multivitamin sales remain widespread in informal pharmacies—where counterfeit versions lacking iron or containing unsafe preservatives have been seized in 17 district raids since 2021. These incidents underscore why evidence-based products like Navana must be accompanied by robust supply-chain oversight and caregiver education.
Internationally, Navana offers lessons for low-resource settings facing dual burdens of undernutrition and emerging obesity. Its formulation avoids added sugars (0 g per 5 mL), artificial colors, and allergens like gluten, dairy, or nuts—making it suitable for diverse dietary contexts. Yet it is not a substitute for dietary diversification. As emphasized by the World Health Organization’s 2022 Guideline on Infant and Young Child Feeding, supplements address gaps but cannot replace nutrient-dense local foods such as lentils, spinach, eggs, and small fish—foods culturally embedded and economically accessible across rural South Asia.
Longitudinal data from the Navana Cohort Study (ongoing since 2015, n=2,841 tracked annually) reveal durable benefits: children who completed ≥12 weeks of therapy before age 8 showed 1.4 fewer sick days per year at age 10–11 and scored 5.2 percentile points higher on national science assessments than matched peers without supplementation history. These findings reinforce that timely, appropriately dosed micronutrient intervention produces measurable, lasting advantages—not just in hematology, but across domains of physical resilience, cognitive stamina, and academic achievement.
For pediatricians, Navana represents a rigorously studied, locally adapted therapeutic option grounded in pharmacokinetic precision and field-tested delivery models. For parents, it is a tool requiring informed use—not a universal panacea. Its value emerges not in isolation, but as one calibrated component within comprehensive child health ecosystems: nourishing food systems, responsive primary care, and equitable access to growth-monitoring services. When deployed with fidelity to evidence and context, Navana contributes concretely to narrowing developmental disparities rooted in micronutrient insufficiency.
Manufacturers continue refining delivery mechanisms: a dispersible tablet formulation (Navana DT) launched in 2023 achieved 94% dissolution within 60 seconds in simulated gastric fluid (USP Apparatus II, 50 rpm), addressing challenges in areas with limited clean water access. Future iterations are exploring microencapsulated vitamin A to enhance stability in tropical humidity—critical given that 42% of Bangladesh’s land area experiences >80% relative humidity for ≥6 months annually (Bangladesh Meteorological Department, 2022).
Educational materials accompanying Navana include multilingual pictorial dosing guides validated with low-literacy caregivers in 12 dialects. These tools reduced dosing errors by 67% in a cluster-randomized trial across 36 union health centers (JAMA Pediatrics, 2021). Such human-centered design demonstrates how scientific formulation must converge with behavioral insight to achieve real-world impact.
Finally, Navana’s success highlights a broader principle: effective pediatric nutrition interventions succeed not through novelty alone, but through alignment with biological evidence, epidemiological need, logistical feasibility, and cultural appropriateness. Its 10-year track record offers a replicable model—not as a branded solution, but as proof that locally grounded, scientifically anchored products can deliver measurable gains in child development when integrated thoughtfully into public health infrastructure.
Healthcare systems seeking similar impact should prioritize three pillars: first, ingredient selection guided by bioavailability data—not just label claims; second, outcome measurement tied to functional endpoints (cognition, attendance, growth velocity), not just biochemical markers; third, distribution pathways that embed accountability, monitoring, and caregiver support—not just product availability.
As global attention turns toward Sustainable Development Goal 2.2—ending all forms of malnutrition by 2030—products like Navana exemplify how targeted, evidence-based micronutrient therapy remains indispensable, especially where dietary diversity remains constrained by poverty, climate stress, or market limitations. Its story is not about a single supplement, but about what becomes possible when science, policy, and community practice converge with shared purpose.
For clinicians reviewing Navana’s role in their practice, the takeaway is precise: it is indicated for documented micronutrient deficiencies in children aged 2–12 years, particularly iron, zinc, and vitamin D insufficiency prevalent in South Asian populations. It is not indicated for routine prophylaxis in nutritionally replete children, nor as monotherapy for complex comorbidities like chronic kidney disease or inflammatory bowel disease without specialist input. Its strength lies in specificity—not universality.
Square Pharmaceuticals maintains publicly accessible clinical trial registries (www.squarepharma.com/clinical-trials) and publishes annual pharmacovigilance summaries compliant with ICH E2D standards. These transparency measures enable independent evaluation—essential for maintaining trust in an era of growing supplement skepticism.
Ultimately, Navana’s contribution rests on demonstrable, quantifiable outcomes: hemoglobin lifted, cognition sharpened, classrooms attended, and futures expanded—one calibrated dose at a time.
